Synaptic proteins in CSF relate to Parkinson’s disease stage markers
Open Access
- 8 February 2017
- journal article
- research article
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 3 (1) , 1-5
Abstract
Recent findings of morphological and functional changes in Parkinson’s disease brains have shown altered synapse formation, but their role in cognitive decline is still an area under exploration. Here we measured the concentration of three key synaptic proteins, Rab3A, SNAP25 and neurogranin by enzyme-linked immunosorbent assay, in cerebrospinal fluid from a total of 139 participants (87 controls and 52 Parkinson’s disease patients out of which 30 were drug-naïve) and explored their associations with motor and cognitive symptoms. Associations with motor disease stage (assessed by Hoehn and Yahr scale) and cognitive performance (assessed by the Montreal Cognitive Assessment scores) were explored. An overall increase in the concentration of SNAP25 was found in Parkinson’s disease patients (p = 0.032). Increased neurogranin levels were found in the drug naïve patients subgroup (p = 0.023). Significant associations were observed between increased concentration of neurogranin and cognitive impairment in total Parkinson’s disease group (p = 0.017), as well as in the drug naïve (p = 0.021) and with motor disease stage (p = 0.041). There were no significant disease-driven changes observed in the concentration of Rab3a. Concentrations SNAP25 and neurogranin were increased in cerebrospinal fluid of Parkinson’s disease patients in a disease specific manner and related to cognitive and motor symptom severity. Future longitudinal studies should explore whether cerebrospinal fluid synaptic proteins can predict cognitive decline in Parkinson’s disease.Keywords
This publication has 32 references indexed in Scilit:
- Neuronal activity drives matching of pre- and postsynaptic function during synapse maturationNature Neuroscience, 2011
- LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling PoolJournal of Neuroscience, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest studyJournal of Neurology, Neurosurgery & Psychiatry, 2010
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s diseaseBrain, 2010
- Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of NeurodegenerationPLOS ONE, 2009
- Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient miceProceedings of the National Academy of Sciences, 2007
- Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairmentNeurology, 2007
- Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1Neuron, 2005
- Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body diseaseNeurobiology of Disease, 2004